Expert review of vaccines · 2026
ACAM2000 vaccine safety and immunogenicity considerations for smallpox and mpox.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Komlenovic Vanja, McCarty James, Cassie David, Anantha Ravi, Yeo Kevin, Rodriguez Mario, Drobic Bojan
Аннотация
INTRODUCTION: Smallpox, eradicated globally in 1980, remains a major biodefense concern due to retained Variola virus stocks and the absence of population immunity following cessation of routine vaccination. Monkeypox virus (MPXV), a related orthopoxvirus, has reemerged as a global public health threat, with major outbreaks in 2022 and renewed spread from 2024 onward.
AREAS COVERED: This review evaluates ACAM2000®, a second-generation live smallpox vaccine, summarizing its development, immunogenicity, efficacy, safety, regulatory status, and potential role in mpox prevention.
EXPERT OPINION: ACAM2000 remains a critical medical countermeasure for smallpox preparedness and a valuable, though selective, tool for mpox prevention. Its high immunogenicity, rapid protection, and broad orthopoxvirus coverage must be balanced against a well-characterized safety risk profile.
AREAS COVERED: This review evaluates ACAM2000®, a second-generation live smallpox vaccine, summarizing its development, immunogenicity, efficacy, safety, regulatory status, and potential role in mpox prevention.
EXPERT OPINION: ACAM2000 remains a critical medical countermeasure for smallpox preparedness and a valuable, though selective, tool for mpox prevention. Its high immunogenicity, rapid protection, and broad orthopoxvirus coverage must be balanced against a well-characterized safety risk profile.